Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: August

by | Sep 29, 2015

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...

Micromanagement of bioethics isn’t ethical

by | Sep 10, 2015

. Bioethicists have had ample time this summer for self-reflection, following Steven Pinker’s op-ed in The Boston Globe that’s informally become known as the “Get out of the way” article. I’ve always found Pinker to be one of my favourite authors due to the fact his...

Right Turn: Thoughts from an engineer on #ILookLikeAnEngineer

by | Aug 28, 2015

. Camila Londono is currently an intern at CCRM, taking a break from working on her PhD at the Institute of Biomaterials and Biomedical Engineering at the University of Toronto under the supervision of Dr. Alison McGuigan. Her research focuses on understanding what...

Update from the Clinic: July

by | Aug 25, 2015

. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...

Cell Therapy Deal Review: July

by | Aug 18, 2015

. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...